Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Background. Cardiac contractility modulation (CCM) is a device therapy for systolic heart failure (HF) in patients with narrow QRS. We aimed to perform an updated meta-analysis of the randomized clinical trials (RCTs) to assess the efficacy and safety of CCM therapy. Methods. We conducted a systemat...

Full description

Saved in:
Bibliographic Details
Main Authors: Ramy Mando, Akshay Goel, Fuad Habash, Marwan Saad, Karam Ayoub, Srikanth Vallurupalli, Waddah Maskoun
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Cardiovascular Therapeutics
Online Access:http://dx.doi.org/10.1155/2019/9769724
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850177263977365504
author Ramy Mando
Akshay Goel
Fuad Habash
Marwan Saad
Karam Ayoub
Srikanth Vallurupalli
Waddah Maskoun
author_facet Ramy Mando
Akshay Goel
Fuad Habash
Marwan Saad
Karam Ayoub
Srikanth Vallurupalli
Waddah Maskoun
author_sort Ramy Mando
collection DOAJ
description Background. Cardiac contractility modulation (CCM) is a device therapy for systolic heart failure (HF) in patients with narrow QRS. We aimed to perform an updated meta-analysis of the randomized clinical trials (RCTs) to assess the efficacy and safety of CCM therapy. Methods. We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) between January 2001 and June 2018. Outcomes of interest were peak oxygen consumption (peak VO2), 6-Minute Walk Distance (6MWD), Minnesota Living with Heart Failure Questionnaire (MLHFQ), HF hospitalizations, cardiac arrhythmias, pacemaker/ICD malfunctioning, all-cause hospitalizations, and mortality. Data were expressed as standardized mean difference (SMD) or odds ratio (OR). Results. Four RCTs including 801 patients (CCM n = 394) were available for analysis. The mean age was 59.63 ± 0.84 years, mean ejection fraction was 29.14 ± 1.22%, and mean QRS duration was 106.23 ± 1.65 msec. Mean follow-up duration was six months. CCM was associated with improved MLWHFQ (SMD -0.69, p = 0.0008). There were no differences in HF hospitalizations (OR 0.76, p = 0.12), 6MWD (SMD 0.67, p = 0.10), arrhythmias (OR 1.40, p = 0.14), pacemaker/ICD malfunction/sensing defect (OR 2.23, p = 0.06), all-cause hospitalizations (OR 0.73, p = 0.33), or all-cause mortality (OR 1.04, p = 0.92) between the CCM and non-CCM groups. Conclusions. Short-term treatment with CCM may improve MLFHQ without significant difference in 6MWD, arrhythmic events, HF hospitalizations, all-cause hospitalizations, and all-cause mortality. There is a trend towards increased pacemaker/ICD device malfunction. Larger RCTs might be needed to determine if the CCM therapy will be beneficial with longer follow-up.
format Article
id doaj-art-c27c80098b27461f89418ee69ee4ab08
institution OA Journals
issn 1755-5914
1755-5922
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Cardiovascular Therapeutics
spelling doaj-art-c27c80098b27461f89418ee69ee4ab082025-08-20T02:19:02ZengWileyCardiovascular Therapeutics1755-59141755-59222019-01-01201910.1155/2019/97697249769724Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsRamy Mando0Akshay Goel1Fuad Habash2Marwan Saad3Karam Ayoub4Srikanth Vallurupalli5Waddah Maskoun6Department of Internal Medicine, Beaumont Health System, Royal Oak, MI, USADepartment of Cardiovascular Medicine, University of Arkansas for Medical Sciences, USADepartment of Cardiovascular Medicine, University of Arkansas for Medical Sciences, USADepartment of Cardiovascular Medicine, University of Arkansas for Medical Sciences, USADepartment of Cardiovascular Medicine, University of Kentucky, Lexington, KY, USADepartment of Cardiovascular Medicine, University of Arkansas for Medical Sciences, USADepartment of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI, USABackground. Cardiac contractility modulation (CCM) is a device therapy for systolic heart failure (HF) in patients with narrow QRS. We aimed to perform an updated meta-analysis of the randomized clinical trials (RCTs) to assess the efficacy and safety of CCM therapy. Methods. We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) between January 2001 and June 2018. Outcomes of interest were peak oxygen consumption (peak VO2), 6-Minute Walk Distance (6MWD), Minnesota Living with Heart Failure Questionnaire (MLHFQ), HF hospitalizations, cardiac arrhythmias, pacemaker/ICD malfunctioning, all-cause hospitalizations, and mortality. Data were expressed as standardized mean difference (SMD) or odds ratio (OR). Results. Four RCTs including 801 patients (CCM n = 394) were available for analysis. The mean age was 59.63 ± 0.84 years, mean ejection fraction was 29.14 ± 1.22%, and mean QRS duration was 106.23 ± 1.65 msec. Mean follow-up duration was six months. CCM was associated with improved MLWHFQ (SMD -0.69, p = 0.0008). There were no differences in HF hospitalizations (OR 0.76, p = 0.12), 6MWD (SMD 0.67, p = 0.10), arrhythmias (OR 1.40, p = 0.14), pacemaker/ICD malfunction/sensing defect (OR 2.23, p = 0.06), all-cause hospitalizations (OR 0.73, p = 0.33), or all-cause mortality (OR 1.04, p = 0.92) between the CCM and non-CCM groups. Conclusions. Short-term treatment with CCM may improve MLFHQ without significant difference in 6MWD, arrhythmic events, HF hospitalizations, all-cause hospitalizations, and all-cause mortality. There is a trend towards increased pacemaker/ICD device malfunction. Larger RCTs might be needed to determine if the CCM therapy will be beneficial with longer follow-up.http://dx.doi.org/10.1155/2019/9769724
spellingShingle Ramy Mando
Akshay Goel
Fuad Habash
Marwan Saad
Karam Ayoub
Srikanth Vallurupalli
Waddah Maskoun
Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Cardiovascular Therapeutics
title Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
title_full Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
title_fullStr Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
title_full_unstemmed Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
title_short Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
title_sort outcomes of cardiac contractility modulation a systematic review and meta analysis of randomized clinical trials
url http://dx.doi.org/10.1155/2019/9769724
work_keys_str_mv AT ramymando outcomesofcardiaccontractilitymodulationasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT akshaygoel outcomesofcardiaccontractilitymodulationasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT fuadhabash outcomesofcardiaccontractilitymodulationasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT marwansaad outcomesofcardiaccontractilitymodulationasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT karamayoub outcomesofcardiaccontractilitymodulationasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT srikanthvallurupalli outcomesofcardiaccontractilitymodulationasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT waddahmaskoun outcomesofcardiaccontractilitymodulationasystematicreviewandmetaanalysisofrandomizedclinicaltrials